Cipla inks agreement with US-based Salix Pharmaceuticals

19 Sep 2014 Evaluate

Cipla, a global pharmaceutical company, has signed an agreement with Salix Pharmaceuticals, Inc., a US-based speciality pharmaceutical company. Under the agreement, Cipla has granted Salix exclusive rights under certain patent applications in the ‘Rifaximin Complexes’ patent family controlled by Cipla.

The grant is on a worldwide basis, excluding the countries of Asia (other than Japan) and Africa. Salix is required to make an up-front payment and, upon achievement, additional regulatory milestone payments to Cipla in respect of the new license agreement regarding the ‘Rifaximin Complexes’ patent rights. Salix also will pay a royalty on net sales of products covered by the ‘Rifaximin Complexes’ patents licensed to Salix.

Last year, Cipla announced the expansion of its existing collaboration with MEDA by granting global commercialisation rights for a proprietary combination nasal spray product (fluticasone and azelastine), Dymista.

Cipla Share Price

1312.85 -2.00 (-0.15%)
27-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1639.30
Dr. Reddys Lab 1240.00
Cipla 1312.85
Zydus Lifesciences 893.45
Lupin 2147.60
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×